MDMA-AT for PTSD in Young Adults With Childhood Trauma

This study is testing a new, emerging treatment for young adults (ages 18-26) with Posttraumatic Stress Disorder (PTSD). The treatment is combining the substance, MDMA, with up to three psychotherapy sessions, also known as MDMA-Assisted Therapy (MDMA-AT).

The main questions it aims to answer are:

• Is the treatment safe and feasible to administer?
• Does the treatment improve PTSD symptoms?

Participants will be asked to:

• Complete screening procedures, including a medical and psychiatric evaluation to ensure safe participation
• Attend up to three preparatory talk therapy sessions prior to the first MDMA-AT dosing session
• Attend three integration talk therapy sessions after each MDMA-AT dosing session
• Attend up to three total MDMA-AT dosing sessions
• Complete assessments from baseline to 38-weeks post-baseline
• Complete a fMRI scan at baseline and at 18-weeks post-treatment
• Complete self-report measures and ecological momentary assessments (EMAs) across the study period